FMP
Charles River Laboratories International, Inc.
CRL
NYSE
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
171.04 USD
4.11 (2.4%)
2024
2023
2022
2021
734.58M
683.9M
619.64M
760.8M
25.29M
480.37M
492.61M
398.84M
361.74M
314.12M
303.87M
265.54M
-67.43M
-50.9M
-35.88M
-24.01M
69.89M
72.05M
73.62M
71.47M
-30.33M
-102.38M
-152.55M
42.94M
21.61M
-33.43M
-150.57M
-26.63M
16.8M
-62.3M
-78.52M
-25.16M
-14.27M
-20.43M
-2.65M
44.9M
-54.47M
13.78M
79.19M
49.83M
375.41M
-29.36M
-62.02M
6.01M
-245.09M
-563.15M
-607.92M
-1.44B
-232.97M
-318.53M
-324.73M
-228.77M
-5.48M
-194.78M
-120.12M
-1.17B
-52.88M
-54.22M
-158.27M
-45.55M
41.69M
6.67M
4.55M
6.53M
4.55M
-2.29M
-9.35M
264k
-550.93M
-85.52M
-42.4M
672.6M
-412.19M
-75.32M
-2.93B
-6.24B
0
0
0
0
-119.17M
-24.16M
-38.65M
-40.71M
0
0
0
0
-19.56M
13.96M
-23.54M
43.32M
501.61M
365.37M
294.91M
532.03M
734.58M
683.9M
619.64M
760.8M
-232.97M
-318.53M
-324.73M
-228.77M
284.48M
241.21M
246.31M
233.12M
205.57M
284.48M
241.21M
246.31M
-78.91M
43.27M
-5.1M
13.2M
2024
2023
2022
2021
1.89B
1.43B
980.75M
625.41M
22.2M
474.62M
486.23M
390.98M
-119.17M
-24.16M
-38.65M
-40.71M
0
0
0
0
1.81B
1.89B
1.43B
980.75M
-194.29M
430.16M
413.5M
314.63M
2024
2023
2022
2021
2.02B
2.03B
1.86B
1.58B
361.74M
314.12M
303.87M
265.54M
-232.97M
-318.53M
-324.73M
-228.77M
1.89B
2.04B
1.88B
1.55B
2024
2023
2022
2021
-248.44M
245.14M
138.02M
902.71M
3.1B
2.85B
2.71B
1.81B
2.85B
3.1B
2.85B
2.71B
All figures are in USD.